Use Of Thromboelastography in the Evaluation And Management of Patients With Traumatic Brain Injury: A Systematic Review

Supplemental Digital Content

Jeremy W. Cannon, MD, SM^{1,2,3} João D. Dias, PhD⁴ Monisha A. Kumar, MD⁵ Mark Walsh, MD⁶ Scott G. Thomas, MD⁷ Bryan A. Cotton, MD⁸ James M. Schuster, MD, PhD⁹ Susan L. Evans, MD¹⁰ Martin A. Schreiber, MD^{3,11} Elisabeth H. Adam, MD¹² Kai Zacharowski, MD, PhD¹² Jan Hartmann, MD⁴ Herbert Schöchl, MD^{13,14} Lewis J. Kaplan, MD^{1,2}

¹Department of Surgery, Division of Traumatology, Surgical Critical Care & Emergency Surgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

²Department of Surgery, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA

³Department of Surgery, F. Edward Hébert School of Medicine at the Uniformed Services University of the Health Sciences, Bethesda, MD, USA

⁴Medical Affairs & Clinical Development, Haemonetics Corporation, Boston, MA, USA

⁵Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

⁶Indiana University School of Medicine, South Bend, Notre Dame Campus, Mishawaka, IN, USA

⁷Memorial Hospital of South Bend, South Bend, IN, USA

⁸Department of Surgery, McGovern Medical School, UTHealth, Houston, TX, USA

⁹Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

¹⁰Department of Surgery, Carolinas Medical Center, Charlotte, NC, USA

¹¹Department of Surgery, Division of Trauma, Critical Care and Acute Care Surgery, School of Medicine, Oregon Health & Science University, Portland, OR, USA

¹²Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt, Goethe-University Frankfurt, Frankfurt/Main, Germany

¹³Department of Anesthesiology and Intensive Care Medicine, AUVA Trauma Centre Salzburg, Academic Teaching Hospital of the Paracelsus Medical University, Salzburg, Austria

¹⁴Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, Vienna, Austria

Supplemental Methods

Results from studies considered for quantitative analysis were abstracted by two authors (J.W.C. and J.D.D.). Review Manager (RevMan, Cochrane Collaboration, version 5.4.1) was used for meta-analysis calculations. A random-effects methodology was used to assess mean differences in TEG and TEG-PM values between study groups and to evaluate the prognostic role of TEG and TEG-PM given inter-study heterogeneity. Mantel-Haenszel fixed-effects metaanalysis was used to evaluate 28-day mortality in TBI patients managed with VHA-guided resuscitation in two randomized control trials. Publication bias was assessed with funnel plot analysis. For studies reporting median and interquartile range, mean difference was calculated using the methodology endorsed by the Cochrane Collaboration (Wan X, Wang W, Liu J, et al.: Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med. Res. Methodol. 2014; 14:135). Summary mean difference figures were created with the forestplot package in R 4.0.3 (The R Foundation for Statistical Computing, http://www.R-project.org). Quality of the evidence was assessed using the GRADE methodology (GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University, 2020 [developed by Evidence Prime, Inc.]. Available from gradepro.org).


		TBI			hy Con			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
2.1.1 R (min)									
Castellino 2014	5.7	1.5	70	7.3	1.8	10	24.5%	-1.60 [-2.77, -0.43]	•
Davis 2013	5.8	1.4	50	7.3	1.3	10	31.8%	-1.50 [-2.39, -0.61]	•
Nekludov 2007 Subtotal (95% CI)	6.3	1.9	20 140	7.7	2	10 30	18.2% 74.5%	-1.40 [-2.89, 0.09] -1.51 [-2.15, -0.87]	1
Heterogeneity. Tau ²	- 0.001.0	hi? -		f _ 7 /6				-1.51 [-2.15, -0.67]	
Test for overall effec					= 0.9	o), i =	0/6		
2.1.2 ACT (sec)									
Subtotal (95% CI)			0			0		Not estimable	
Heterogeneity: Not a	pplicable								
Test for overall effec	t: Not app	olicable	2						
2.1.3 K (sec)			_						
Davis 2013	114	42.6	50	126	37.8	10		-12.00 [-38.24, 14.24]	
Subtotal (95% CI)			50			10	0.1%	-12.00 [-38.24, 14.24]	
Heterogeneity: Not a									
Test for overall effec	t: Z = 0.9	00 (P =	0.37)						
2.1.4 Alpha (deg)									
Davis 2013	63.1		50	59.1	7.9	10	1.9%	4.00 [-1.61, 9.61]	
Nekludov 2007 Subtotal (95% CI)	62	11	20 70	59	7	10 20	1.4% 3.3%	3.00 [-3.49, 9.49] 3.57 [-0.67, 7.82]	
Heterogeneity: Tau ²	0.00.0	- 1.12		f 1/5				3.37 [-0.07, 7.82]	•
Test for overall effec				I = I (F	= 0.0.	2J, I =	0/6		
2.1.5 MA (mm)									
Castellino 2014	60.9	7.3	70	63	3.6	10	6.7%	-2.10 [-4.91, 0.71]	-
Davis 2013	61.7	7.8	50	63.3	5.1	10	3.8%	-1.60 [-5.43, 2.23]	-
Nekludov 2007	58	8	20	61	3	10	3.6%	-3.00 [-6.97, 0.97]	
Subtotal (95% CI)			140			30	14.1%	-2.19 [-4.16, -0.22]	•
Heterogeneity: Tau ²	= 0.00; 0	:hi² =	0.26, d	f = 2 (F	9 = 0.83	B); I ² =	0%		
Test for overall effec	t: Z = 2.1	.8 (P =	0.03)						
2.1.6 LY30 (% Lysis									
Nekludov 2007	3	3.2	20	1.7	3.4	10	8.1%	1.30 [-1.23, 3.83]	t
Subtotal (95% CI)			20			10	8.1%	1.30 [-1.23, 3.83]	•
Heterogeneity: Not a Test for overall effec		1(P =	0.31)						
Total (95% CI)			420			100	100.0%	-1.22 [-2.00, -0.45]	
Heterogeneity: Tau ²	= 0.29: 0	:hi² =	11.30.	df = 9	(P = 0.3)	26); I ² -	= 20%		Hanna
Test for overall effec									-100 -50 0 50 100 Lower in TBI Higher in TBI
	fferences								

		TBI		Healt	hy Con	trol		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
2.2.1 AA (% Inhib)									
Bartels 2016	40.1	31.5	12	8.4	9.5	8	9.6%	31.70 [12.70, 50.70]	
Castellino 2014	37.2	36.3	70	2.4	1.7	10		34.80 [26.23, 43.37]	
Davis 2013	26.6	19.8	50	2.5	1.9	10	11.8%	24.10 [18.49, 29.71]	
Nekludov 2007 Subtotal (95% CI)	78.6	6.1	20 152	27.4	3.8	10 38	12.0%	51.20 [47.64, 54.76] 35.79 [19.52, 52.06]	
Heterogeneity. Tau ² =	= 248.73	3: Chi²	= 68.4	9. df =	3 (P <	0.000	$(11)^2 = 2$	96%	-
Test for overall effect		·			- • •				
2.2.2 ADP (% Inhib)									
Bartels 2016	75.6	23	12	7.4	8.3	8	10.5%	68.20 [53.97, 82.43]	
Castellino 2014	70.1	42.2	70	23.9	19.3	10	10.3%	46.20 [30.68, 61.72]	
Davis 2013	75.3	45.6	50	14.3	3.8	10	10.8%	61.00 [48.14, 73.86]	
Nekludov 2007	55	4.7	20	36.2	2.3	10	12.1%	18.80 [16.30, 21.30]	+
Stettler 2017	56.3	40.4	80	5.1	4	89	11.4%	51.20 [42.31, 60.09]	
Subtotal (95% CI)			232			127	55.1%	48.68 [25.74, 71.62]	
Heterogeneity: Tau ² =	= 649.48	3; Chi²	= 129.	20, df -	= 4 (P ·	< 0.000	$(001); ^2 =$	97%	
Test for overall effect	Z = 4.3	LG (P <	0.000	1)					
Total (95% CI)			384					42.67 [29.85, 55.49]	
Heterogeneity: Tau² =	= 353.38	3; Chi²	= 291.	51, df :	= 8 (P ·	< 0.000	001); ² =	97%	-100 -50 0 50 10
Test for overall effect	Z = 6.5	52 (P <	0.000	01)					Lower in Isolated TBI Higher in Isolated TBI
Test for subaroup dif	ferences	· Chi ² -	- 0.81	df = 1	P = 0	271 12	- 0%		concernit isolated and angler in isolated and

Supplemental Figure 1. TEG and TEG-PM values in TBI patients vs Healthy Controls


tudy or Subgroup .1.1 R (min)	Mean	TBI SD	Total		na Cont SD		Weight	Mean Difference IV, Random, 95% C	1	Mean Difference IV, Random, 95% CI
e Oliveira Manoel 2015	8.2	14.5	137	7	11.9	160	6.2%	1.20 [-1.85, 4.25]	+
lekludov 2007	6.3	1.9	20	5.8	1.2	10	11.4%			+
alle 2014	7.1	2.3	68	7.2	2.9	80	12.1%			t t
ubtotal (95% CI)			225			250	29.7%	0.17 [-0.49, 0.82]	
eterogeneity: Tau ² = 0.0 est for overall effect: Z =				: (P = 0.	56); l² =	= 0%				
.1.2 ACT (sec)										
amuels 2019	123.3	17.6	45 45	120.7	11.2	479 479	3.1%			T I
ubtotal (95% CI)	bla		43			4/9	3.1%	2.60 [-2.64, 7.84	1	•
eterogeneity: Not applica est for overall effect: Z =		= 0.33	3)							
.1.3 K (sec)										
e Oliveira Manoel 2015	194.4			158.4		160	0.1%			
alle 2014 J btotal (95% CI)	108	31.8	68 205	126	49.8	80 240	0.6% 0.7%	-18.00 [-31.27, -4.73 5.78 [-46.76, 58.32		
eterogeneity: Tau ² = 123 est for overall effect: Z =			.64, df	' = 1 (P	= 0.010			5.76 [-40.70, 56.52		
.1.4 Alpha (deg)										
e Oliveira Manoel 2015	55	15.5	137	58	16.3	160	5.1%	-3.00 [-6.62, 0.62	1	
ekludov 2007	62		20	62	6	10	2.4%		-	+
amuels 2019		12.3	45	71.7	6.8	479	5.1%			+
alle 2014	63.6	6.9	68	58.9	10.7	80	6.7%			<u> </u> +
ubtotal (95% CI)			270			729	19.3%	0.19 [-3.78, 4.16	5]	•
eterogeneity: Tau ² = 12. est for overall effect: Z =	•			= 3 (P =	0.005)	; ² = 7	7%			
.1.5 MA (mm)										
e Oliveira Manoel 2015	57.4	13.4	137	55 1	14.1	160	6.1%	-1.70 [-4.83, 1.43	1	-
ekludov 2007	58		20	58	4	100	4.1%	• •		+
amuels 2019	57.2		45	62.1	7.3	479	4.8%	• •		
alle 2014	61.9	б.б	68	57.7	б.9	80	8.4%		i i	-
ubtotal (95% CI)			270			729	23.3%	-0.45 [-4.66, 3.77	1	•
leterogeneity: Tau² = 15. est for overall effect: Z =				= 3 (P =	0.0001	1); 12 =	85%			
.1.6 LY30 (% Lysis)										
e Oliveira Manoel 2015	2.4	8.4	137	2.4	10.1	160	8.6%	0.00 [-2.10, 2.10	1	+
ekludov 2007	3	3.2	20	4	7.7	10	3.3%	-1.00 [-5.97, 3.97	'1	+
amuels 2019	1.9	3	45	1.9	1.8	479	12.0%			t
ubtotal (95% CI)	A. 61.2	A 15	202		0.211.12	649	23.9%	-0.03 [-0.84, 0.78	9	
eterogeneity: Tau ² = 0.0 est for overall effect: Z =				; (P = 0.	93); 1* =	= 0%				
			1217			3076	100.0%	0.19 [-0.86, 1.24		
								0.15 [-0.00, 1.24		
eterogeneity: Tau ² = 2.2			б, df =	16(P <	0.0001	l); ² =		0.15 [-0.00, 1.24	-100	-50 0 50 1
eterogeneity: Tau ² = 2.2 est for overall effect: Z =	0.35 (P	= 0.73	5, df = 3)			_		0.15 [0.00, 1.24	-	-50 0 50 2 Lower in TBI Higher in TBI
eterogeneity: Tau ² = 2.2 est for overall effect: Z =	0.35 (P	= 0.73	5, df = 3)			_		0.15 [0.00, 124	-	
eterogeneity: Tau ² = 2.2 est for overall effect: Z = est for subgroup differen tudy or Subgroup M	0.35 (P Ices: Chi ² T B	= 0.73 ² = 1.1	5, df = 3) 2, df =	5 (P =	0.95), l ^a Contro	² = 0%	66%	Mean Difference IV, Random, 95% CI	-	
eterogeneity: Tau ² = 2.2 est for overall effect: Z = est for subgroup differen tudy or Subgroup M .2.1 AA (% Inhib)	0.35 (P Ices: Chi ² T B	= 0.73 ² = 1.1 31 <u>5D To</u>	5, df = 3) 2, df =	5 (P = Trauma Iean	0.95), l ^a Contro	² = 0% Di otal V	66% Veight	Mean Difference	-	Lower in TBI Higher in TBI Mean Difference
eterogeneity: Tau ² = 2.2 est for overall effect: Z = est for subgroup differen tudy or Subgroup M .2.1 AA (% Inhib) artels 2016 4	0.35 (P nces: Chi ² TB Iean	= 0.73 ² = 1.1 <u>SD To</u> 1.5	5, df = 3) 2, df = 7 otal M	5 (P = Trauma Iean 21.3	0.95), l ^a Contro SD Te	² = 0% otal V 13	66% Veight 16.5%	Mean Difference IV, Random, 95% CI	-	Lower in TBI Higher in TBI Mean Difference
eterogeneity: Tau ² = 2.2 est for overall effect: Z = est for subgroup differen tudy or Subgroup M 2.1 AA (% Inhib) artels 2016 4 ekludov 2007 7	0.35 (P inces: Chi ² TB Iean (1) 40.1 31	= 0.73 ² = 1.1 <u>SD To</u> 1.5	5, df = 3) 2, df = 1 1 2	5 (P = Trauma Iean 21.3	0.95), I ² Contro SD To 29	² = 0% bl otal V 13 10	66% Veight 16.5% 22.8%	Mean Difference IV, Random, 95% CI 18.80 [-4.99, 42.59]	-	Lower in TBI Higher in TBI Mean Difference
eterogeneity: Tau ² = 2.2 est for overall effect: Z = est for subgroup differen tudy or Subgroup M (2.1 AA (% Inhib) artels 2016 4 ekludov 2007 7 ubtotal (95% CI) eterogeneity: Tau ² = 0.	0.35 (P nces: Chi ² 16an 40.1 31 78.6 6 .00; Chi ²	= 0.73 ² = 1.1 ³¹ <u>5D</u> Tc 1.5 6.1 ² = 0.5	5, df = 3) 2, df = otal M 12 2 20 9 32 52, df =	Trauma fean 21.3 50.9 = 1 (P =	0.95), l ² Contro SD To 29 4.9	² = 0% bi otal V 13 10 23	66% Weight 16.5% 22.8% 39.3%	Mean Difference IV, Random, 95% CI 18.80 [-4.99, 42.59] 27.70 [23.65, 31.75]	-	Lower in TBI Higher in TBI Mean Difference
tudy or Subgroup M artels 2016 4 ekludov 2007 7 ubtotal (95%Cl) eterogeneity: Tau ² = 0. est for overall effect: Z	0.35 (P nces: Chi ² 16an 40.1 31 78.6 6 .00; Chi ²	= 0.73 ² = 1.1 ³¹ <u>5D</u> Tc 1.5 6.1 ² = 0.5	5, df = 3) 2, df = otal M 12 2 20 9 32 52, df =	Trauma fean 21.3 50.9 = 1 (P =	0.95), l ² Contro SD To 29 4.9	² = 0% bi otal V 13 10 23	66% Weight 16.5% 22.8% 39.3%	Mean Difference IV, Random, 95% CI 18.80 [-4.99, 42.59] 27.70 [23.65, 31.75]	-	Lower in TBI Higher in TBI Mean Difference
.2.1 AA (% Inhib) artels 2016 4 lekludov 2007 7 ubtotal (95% CI) 7 leterogeneity: Tau ² = 0. 0. est for overall effect: Z 2 .2.2 ADP (% Inhib) 3 artels 2016 7	0.35 (P ntees: Chi ² 40.1 31 78.6 (.00; Chi ² = 13.49 75.6	= 0.73 ² = 1.1 ³¹ ^{5D} Tc ^{1.5} ^{6.1} ² = 0.5 ² (P < 0 ² ² 23	5, df = 3) 2, df = 12 32 32 2, df = 0.00000 12 (Trauma Mean 21.3 50.9 = 1 (P =)1)	0.95), l ² Contro SD T 29 4.9 = 0.47); 37	$r^{2} = 0\%$ bi otal V 13 10 23 $ ^{2} = 0\%$ 13	66% <u>Veight</u> 16.5% 22.8% 39.3% % 16.4%	Mean Difference IV, Random, 95% CI 18.80 [-4.99, 42.59] 27.70 [23.65, 31.75] 27.45 [23.46, 31.44] 8.00 [-15.96, 31.96]	-	Lower in TBI Higher in TBI Mean Difference
eterogeneity: Tau ² = 2.2 est for overall effect: Z = est for subgroup differen tudy or Subgroup M 2.1 AA (% Inhib) artels 2016 4 lekludov 2007 7 ubtotal (95% CI) eterogeneity: Tau ² = 0. est for overall effect: Z = .2.2 ADP (% Inhib) artels 2016 7 lekludov 2007	0.35 (P trees: Chi ² TB 1ean 40.1 31 78.6 (.00; Chi ² = 13.49 75.6 55 4	$= 0.73$ $= 1.1$ $\frac{31}{5D Tc}$ $\frac{1.5}{6.1}$ $= 0.5$ $(P < 0)$ 23 4.7	5, df = 3) 2, df = Dtal M 12 2 32 32 52, df = 0.00000 12 4 20	Trauma Iean 21.3 50.9 = 1 (P = 01) 67.6 58	0.95), I ² Contro SD Tr 29 4.9 0.47); 37 4.3	$2^{2} = 0\%$ bi otal V 13 10 23 $ ^{2} = 0\%$ 13 10	66% Veight 16.5% 22.8% 39.3% %	Mean Difference IV, Random, 95% CI 18.80 [-4.99, 42.59] 27.70 [23.65, 31.75] 27.45 [23.46, 31.44] 8.00 [-15.96, 31.96] -3.00 [-6.37, 0.37]	-	Lower in TBI Higher in TBI Mean Difference
eterogeneity: Tau ² = 2.2 est for overall effect: Z = est for subgroup differen 2.1 AA (% Inhib) artels 2016 4 ekludov 2007 7 ubtotal (95% CI) eterogeneity: Tau ² = 0. est for overall effect: Z = 2.2 ADP (% Inhib) artels 2016 7 ekludov 2007 ettler 2017 5	0.35 (P ntees: Chi ² 40.1 31 78.6 (.00; Chi ² = 13.49 75.6	$= 0.73$ $= 1.1$ $\frac{31}{5D Tc}$ $\frac{1.5}{6.1}$ $= 0.5$ $(P < 0)$ 23 4.7 8.3	5, df = 2, df = 2, df = otal M 12 : 32 32 .2, df = 0.0000 12 (20 - 80 -	Trauma Mean 21.3 50.9 = 1 (P =)1)	0.95), i ² Contro SD Ta 29 4.9 • 0.47); 37 4.3 4.3 4.3 17.9	$r^{2} = 0\%$ bi otal V 13 10 23 $ ^{2} = 0\%$ 13 10 223	66% Veight 16.5% 22.8% 39.3% % 16.4% 22.9% 21.4%	Mean Difference IV, Random, 95% CI 18.80 [-4.99, 42.59] 27.70 [23.65, 31.75] 27.45 [23.46, 31.44] 8.00 [-15.96, 31.96] -3.00 [-6.37, 0.37] 9.20 [-1.29, 19.69]	-	Lower in TBI Higher in TBI Mean Difference
eterogeneity: Tau ² = 2.2 est for overall effect: Z = est for subgroup differen (2.1 AA (% Inhib) artels 2016 4 ekludov 2007 7 ubtotal (95% CI) eterogeneity: Tau ² = 0. est for overall effect: Z = (2.2 ADP (% Inhib) artels 2016 7 ekludov 2007 ettler 2017 5 ubtotal (95% CI) eterogeneity: Tau ² = 44	0.35 (P cces: Chi ² TB fean 40.1 31 78.6 6 .00; Chi ² = 13.49 75.6 55 4 51.9 38 4.48; Ch	$= 0.73^{2} = 1.1$ 31 5D Tc 1.5 6.1 2 = 0.5 9 (P < 0 23 4.7 8.3 1)1 ² = 5.	5, df = 3) 2, df = 2, df = 12 20 32 2, df = 0,0000 12 20 80 412 35, df	Trauma Mean 21.3 50.9 = 1 (P = 01) 67.6 58 42.7 4	0.95), i ² Contro SD To 29 4.9 0.47); 37 4.3 47.9	$r^{2} = 0\%$ bi otal V 13 10 23 $ ^{2} = 0\%$ 13 1 0 23 1 3 1 0 23 1 3 23 246	66% Veight 16.5% 22.8% 39.3% % 16.4% 22.9% 21.4% 60.7%	Mean Difference IV, Random, 95% CI 18.80 [-4.99, 42.59] 27.70 [23.65, 31.75] 27.45 [23.46, 31.44] 8.00 [-15.96, 31.96] -3.00 [-6.37, 0.37]	-	Lower in TBI Higher in TBI Mean Difference
eterogeneity: Tau ² = 2.2 est for overall effect: Z = est for subgroup differen 1.1 AA (% Inhib) artels 2016 4 ekludov 2007 7 ubtotal (95% CI) eterogeneity: Tau ² = 0. est for overall effect: Z = .2.2 ADP (% Inhib) artels 2016 7 ekludov 2007 ettler 2017 5 ubtotal (95% CI) eterogeneity: Tau ² = 44 est for overall effect: Z =	0.35 (P cces: Chi ² TB fean 40.1 31 78.6 6 .00; Chi ² = 13.49 75.6 55 4 51.9 38 4.48; Ch	$= 0.73$ $= 1.1$ $SD Tc$ 1.5 6.1 $^{2} = 0.5$ $(P < 0)$ 23 4.7 8.3 1 $hi^{2} = 5.$ $(P = 0.$	5, df = 3) 2, df = 12 : 32 12 : 32 20 : 32 20 : 32 20 : 32 32 33 35, df = 12 : 35, df = 35, df = 35, df = 35, df = 36, df = 36, df = 37, df = 37, df = 37, df = 38, df =	Trauma Mean 21.3 50.9 = 1 (P = 01) 67.6 58 42.7 4	0.95), 1 ² Contro SD To 29 4.9 0.47); 37 4.3 47.9 = 0.07;	$\begin{array}{c} \mathbf{p} \\ $	66% Veight 16.5% 22.8% 39.3% % 16.4% 22.9% 21.4% 60.7% 63%	Mean Difference IV, Random, 95% CI 18.80 [-4.99, 42.59] 27.70 [23.65, 31.75] 27.45 [23.46, 31.44] 8.00 [-15.96, 31.96] -3.00 [-6.37, 0.37] 9.20 [-1.29, 19.69] 2.60 [-7.21, 12.41]	-	Lower in TBI Higher in TBI Mean Difference
eterogeneity: Tau ² = 2.2 est for overall effect: Z = est for subgroup differen 2.1 AA (% inhib) artels 2016 4 ekludov 2007 7 ubtotal (95% CI) eterogeneity: Tau ² = 0. est for overall effect: Z = .2.2 ADP (% inhib) artels 2016 7 ekludov 2007 ettler 2017 5 ubtotal (95% CI) eterogeneity: Tau ² = 44 est for overall effect: Z = otal (95% CI)	0.35 (P tces: Ch ² 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 1	$= 0.73^{2} = 1.1$ 31 31 35 Ttc 36.1 2 = 0.5 6.1 23 4.7 8.3 1 $1i^{2} = 5.$ (P = 0. 1	5, df = 3) 2, df = 1 1 20 20 20 20 20 20 20 20 20 20	Frauma Mean 21.3 50.9 = 1 (P =)1) 67.6 58 42.7 4 = 2 (P	0.95), 1 ² Contro SD T 29 4.9 0.47); 37 4.3 47.9 2 = 0.07;	I I I3 I I I3 I I I I I3 I	66% Veight 16.5% 22.8% 39.3% % 16.4% 22.9% 21.4% 60.7% 63% L00.0%	Mean Difference IV, Random, 95% CI 18.80 [-4.99, 42.59] 27.70 [23.65, 31.75] 27.45 [23.46, 31.44] 8.00 [-15.96, 31.96] -3.00 [-6.37, 0.37] 9.20 [-1.29, 19.69] 2.60 [-7.21, 12.41] 12.01 [-6.03, 30.05]	-	Lower in TBI Higher in TBI Mean Difference
eterogeneity: Tau ² = 2.2 est for overall effect: Z = est for subgroup differen attels 2016 ekludov 2007 abtotal (95% CI) eterogeneity: Tau ² = 0. est for overall effect: Z = 2.2 ADP (% Inhib) artels 2016 ekludov 2007 ekludov 2007 eterogeneity: Tau ² = 0. est for overall effect: Z = ekludov 2007 etkludov 2007 etkludov 2007 etkludov 2007 etklogeneity: Tau ² = 44 est for overall effect: Z =	0.35 (P cces: Ch ² TB fean 40.1 31 78.6 (C .00; Chi ² = 13.49 75.6 51.9 38 4.48; Ch = 0.52 (C 67.11; C	$= 0.73^{2} = 1.1$ 31 SD Tc 1.5 6.1 2 = 0.5 6.1 23 4.7 8.3 1 $h^{2} = 5.$ (P = 0. 1 $h^{2} = 5.$	5, df = 3) 2, df = 1 1 1 20 5 3 2 1 1 1 1 1 1 1 1	Frauma Mean 21.3 50.9 = 1 (P =)1) 67.6 58 42.7 4 = 2 (P	0.95), 1 ² Contro SD T 29 4.9 0.47); 37 4.3 47.9 2 = 0.07;	I I I3 I I I3 I I I I I3 I	66% Veight 16.5% 22.8% 39.3% % 16.4% 22.9% 21.4% 60.7% 63% L00.0%	Mean Difference IV, Random, 95% CI 18.80 [-4.99, 42.59] 27.70 [23.65, 31.75] 27.45 [23.46, 31.44] 8.00 [-15.96, 31.96] -3.00 [-6.37, 0.37] 9.20 [-1.29, 19.69] 2.60 [-7.21, 12.41] 12.01 [-6.03, 30.05]	-	Lower in TBI Higher in TBI Mean Difference


Supplemental Figure 2. TEG and TEG-PM values in TBI patients vs Trauma Controls




	Sev	vere TE	31	Mild-M	oderate	тві		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
4.2.1 AA (% Inhib)									
Castellino 2014	25.5	48.5	29	44.1	50.7	41	13.3%	-18.60 [-42.10, 4.90]	
Davis 2013	38	51.3	28	17	53.7	22	10.3%	21.00 [-8.40, 50.40]	
Kay 2019	41.5	30.2	78	34.8	24.3	41	23.5%	6.70 [-3.31, 16.71]	+ - -
Subtotal (95% CI)			135			104	47.1%	2.60 [-16.06, 21.26]	
Heterogeneity: Tau ² =	= 165.09	9; Chi²	= 5.11	, df = 2 i	P = 0.03	B); 1 ² = 1	61%		
Test for overall effect:	Z = 0.2	27 (P =	0.78)						
4.2.2 ADP (% Inhib)									
Castellino 2014	78.7	41.7	29	56.9	33.9	41	16.8%	21.80 [3.41, 40.19]	
Davis 2013	86.5	45.8	28	49.8	36.6	22	13.7%	36.70 [13.86, 59.54]	
Kay 2019	65.1	39	78	48.4	24.6	41	22.3%	16.70 [5.23, 28.17]	
Subtotal (95% CI)			135			104	52.9%	21.62 [11.48, 31.77]	•
Heterogeneity: Tau ² =	= 13.76;	Chi ² =	2.36,	df = 2 (P	= 0.31	; l ² = 1	5%		
Test for overall effect:	Z = 4.1	18(P <	0.000	1)					
Total (95% CI)			270			208	100.0%	13.69 [1.88, 25.50]	•
Heterogeneity: Tau ² =	= 128.29	9; Chi²	= 14.1	5, df = 5	(P = 0.0	01); l ² =	65%		
Test for overall effect:									-100 -50 Ó 50 100 Lower in Severe TBI Higher in Severe TBI
Test for subgroup diff				df = 1 (f	e = 0.08), $ ^2 = 6$	7.6%		Lower in severe i bil Higher in Severe i Bi

Supplemental Figure 3. TEG and TEG-PM values in Severe TBI vs Mild-Moderate TBI






Supplemental Figure 4. TEG and TEG-PM values in Severe TBI vs Mild-Moderate TBI




Supplemental Figure 5. TEG values in Penetrating TBI vs Blunt TBI




Test for subgroup differences: $Chi^2 = 0.46$, df = 1 (P = 0.50), $I^2 = 0\%$

Supplemental Figure 6. TEG and TEG-PM values in TBI Non-Survivors vs Survivors



Supplemental Figure 7. TEG values in TBI patients with Progression vs No Progression



Supplemental Figure 8. Publication bias assessment of manuscripts describing the outcomes of traumatic brain injury patients managed under a viscoelastic hemostatic assay-guided resuscitation protocol compared to conventional coagulation tests.

Supplemental Table 1: Search Strings

MEDLINE and PubMed Central search string

((head OR crani* OR cerebr* OR brain* OR forebrain* OR hemispher* OR intracran*) AND (injur* OR trauma* OR damag* OR lesion* OR wound* OR destruction* OR oedema* OR edema* OR contusion* OR fracture*) OR craniocerebral trauma [mh]) AND (thromboelasto* OR teg OR thrombelasto* OR plateletmapping)

Embase search string

((head OR crani* OR cerebr* OR brain* OR forebrain* OR hemispher* OR intracran*) AND (injur* OR trauma* OR damag* OR lesion* OR wound* OR destruction* OR oedema* OR edema* OR contusion* OR fracture*) OR 'craniocerebral trauma') AND (thromboelasto* OR teg OR thrombelasto* OR plateletmapping) NOT 'medline'

CENTRAL search string

"brain" in Title Abstract Keyword AND "injur" in Title Abstract Keyword OR "trauma" in Title Abstract Keyword AND "TEG" in Title Abstract Keyword OR "Thromboelastograph" in Title Abstract Keyword - in Cochrane Reviews, Cochrane Protocols, Trials (Word variations have been searched)

Inclusion criteria	Exclusion criteria
Studies of adult humans or human blood samples	Pediatric studies, non-human studies, any studies done in animals
Case series, clinical trials	Reviews, meta-analyses, editorials, responses, comments, congress abstracts
Reports data relevant to traumatic brain injury	No relevant brain injury data
Utilization of standard TEG or TEG-PM (5000 or 6s) in the context of traumatic brain injury assessment, or predicting or improving patient outcomes	No Viscoelastic testing reported Use of viscoelastic testing reported but not directly linked to assessment/treatment of traumatic brain injury Standard TEG or TEG-PM (5000 or 6s) not reported

Supplemental Table 2. Inclusion and Exclusion Criteria for the Literature Search

The PubMed and EMBASE search results were filtered to exclude any manuscript published prior to 1999 (the year the TEG 5000 analyzer was first introduced), manuscripts in non-human subjects, and any language other than English. A second screen was carried out using the same inclusion and exclusion criteria to review the full text of all non-excluded articles. In addition to the articles identified in the search, additional manuscripts were suggested by the authors which had been published later than the search cut-off date, were not PubMed-indexed, or did not have an abstract so they were missed by the initial search. These were added and screened as per the inclusion/exclusion criteria. PRISMA guidelines for systematic reviews were followed in reporting the results. All manuscripts that met the predefined inclusion/exclusion criteria were included for full text review. Article screening was performed by two individuals independent from but financially supported by Haemonetics. Differences in screening selection were adjudicated by a third individual. All authors were involved in the qualitative and quantitative evaluation of the papers selected for inclusion. TEG, thromboelastography; TEG-PM, thromboelastography with platelet mapping

Supplemental Table 3. United States Food and Drug Administration TEG and TEG-PM Indications for Use

TEG 5000

The TEG® 5000 Thromboelastograph® Hemostasis Analyzer System (Haemonetics Corporation, Boston, MA) is a non-invasive diagnostic instrument designed to monitor and analyze the hematological state of a blood sample in order to assist in the assessment of patient clinical hemostasis conditions. The TEG Hemostasis System is indicated for use with adult patients where an evaluation of their blood hemostatic properties is desired. Hemostasis evaluations are commonly used to assess clinical conditions such as post-operative hemorrhage and/or thrombosis during and following cardiovascular surgery, organ transplantation, trauma, and cardiology procedures.

TEG 6s

The indication for TEG 6s System (Haemonetics Corporation, Boston, MA) use is with adult patients (18 years or older) where an evaluation of their blood hemostasis properties is desired. Hemostasis evaluations with the TEG 6s Citrated: K, KH, RT, FF Assay Cartridge and the TEG PlateletMapping® ADP & AA Cartridge are commonly used to assess clinical conditions in cardiovascular surgery and cardiology procedures to assess hemorrhage or thrombosis conditions before, during and following the procedure. Hemostasis evaluation with the TEG 6s Hemostasis System using the Citrated: K, RT, FF Assay Cartridge is used to assess clinical conditions in a trauma setting to assess hemorrhage or thrombosis conditions.

AA, arachidonic acid; ADP, adenosine diphosphate; FF, functional fibrinogen; RT, R-time; TEG, thromboelastography; TEG-PM, thromboelastography with platelet mapping

Supplemental Table 4. Overview of Studies Included for Quantitative Analysis of TEG Profiles in TBI Patients

Manuscript	Type of patients	Study type	SIGN 50 Assessment*
Bartels 2016 (32)	TBI vs non-TBI trauma (consecutively activated level 1 traumas) vs healthy controls; 12 TBI patients	Prospective observational study	++
Castellino 2014 (33)**	Trauma patients with isolated TBI (Severe vs mild-to- moderate) vs healthy controls; 70 TBI patients	Subset of patients from a prospective observational study	+
Davis 2013 (36)**	TBI patients not treated with anticoagulants or platelet inhibitors; 50 TBI patients	Subset of patients from a prospective observational study	+
de Oliveira Manoel 2014 (37)	Isolated severe TBI vs multisystem trauma with severe TBI vs non-TBI trauma; 48 isolated TBI patients, 137 multisystem trauma with TBI	Post-hoc analysis of a large prospective observational study	+
Folkerson 2018 (38)	Blunt vs penetrating TBI; 347 TBI patients	Retrospective study	+
Guillotte 2018 (39)	TBI; 153 patients	Prospective observational study	+
Kay 2019 (26)	Isolated blunt TBI; 119 patients	Retrospective study	+
Martin 2018 (40)	TBI; 534 patients	Retrospective study	+
Nekludov 2007 (41)	Severe isolated TBI vs general trauma without TBI vs chronic alcohol abuse vs healthy controls; 20 TBI patients	Prospective observational study	+
Samuels 2019 (35)	Isolated TBI vs multisystem trauma with TBI vs non-TBI trauma ; 48 isolated TBI, 45 multisystem trauma with TBI	Retrospective study	+
Stettler 2017 (42)	Trauma activations; 80 TBI patients	Retrospective study	+
Valle 2014 (34)	Polytrauma patients with TBI vs non-TBI trauma; 68 TBI patients	Prospective observational study	+

*SIGN 50 methodology quality rating using the case-control study checklist: **High quality** (++): Majority of criteria met. Little or no risk of bias. Results unlikely to be changed by further research. **Acceptable** (+): Most criteria met. Some flaws in the study with an associated risk of bias. Conclusions may change in the light of further studies. **Low quality (0)**: Either most criteria not met or significant flaws relating to key aspects of study design. Conclusions likely to change in the light of further studies.

Numbers in () refer to the reference in the primary manuscript.

**Overlapping study subjects

TBI, traumatic brain injury

Population	R (min)	ACT (sec)	K (sec)	a (deg)	MA (mm)	LY-30 (% Lysis)	AA (% Inhib)	ADP (% Inhib)
TBI vs Healthy Control	₽	ND	-	-	•	-		
TBI vs Trauma Control	-	-	-	-	-	-		-
Severe TBI vs Mild-Moderate TBI	₽	ND	-	-	-	ND	-	
Polytrauma + TBI vs Isolated TBI [†]		-	-	-	-	-	-	
Penetrating TBI vs Blunt TBI	ND	-		➡	₽	-	ND	ND
TBI Non-Survivors vs TBI Survivors [†]	-	ND		₽	-	-	-	
TPI Progression vs No Progression	-	ND	-	-	-	-	ND	ND

Supplemental Table 5. Summary of Relative Admission TEG Profiles in Different Patient Populations

Arrow directionality indicates the abnormality in the first population relative to the second. For example, the R time is shorter in TBI compared to healthy controls. The fill color indicates whether the difference results in a hyper-coagulable state (green) or hypo-coagulable state (red). A dash (-) indicates no measurable difference while ND indicates no data for the parameter in the given population. *Pooled mean difference of questionable clinical significance as the delta is less than 5% of the abnormal threshold for the given parameter. [†]Results based on one study each for both standard TEG parameters and TEG-PM parameters.

Supplemental Table 6. Overview of Studies Included for Quantitative Analysis of Mortality and Progression in TBI Patients

Manuscript	Type of patients	Study type	SIGN 50 Assessment*
Davis 2013 (36)	TBI patients not treated with anticoagulants or platelet inhibitors; 50 TBI patients	Subset of patients from a prospective observational study	+
Rao 2017 (28)	TBI with intracranial hemorrhage; 169 patients	Prospective observational study	++
Webb 2021 (29)	Severe TBI patients (initial CGS <= 8) with an initial CT Head and TEG available; 141 patients	Retrospective study	+

*SIGN 50 methodology quality rating using the case-control study checklist: **High quality** (++): Majority of criteria met. Little or no risk of bias. Results unlikely to be changed by further research. **Acceptable** (+): Most criteria met. Some flaws in the study with an associated risk of bias. Conclusions may change in the light of further studies. **Low quality (0)**: Either most criteria not met or significant flaws relating to key aspects of study design. Conclusions likely to change in the light of further studies. Reject.

Numbers in () refer to the reference in the primary manuscript.

CT, computed tomography; GCS, Glasgow Coma Scale; TBI, traumatic brain injury

Supplemental Table 7. Overview of Included Studies Reporting Management of TBI Patients guided by Viscoelastic Hemostatic Assays

Manuscript	Type of patients	Study type	Risk of Bias Assessment*, **
Baksaas-Aasen 2021 (14)	Trauma patients meeting criteria for massive hemorrhage protocol; 74 TBI patients	Pragmatic RCT	+
Gonzalez 2016 (13)	Injured adults meeting criteria for massive transfusion protocol; 21 TBI patients	Pragmatic RCT	-

* SIGN 50 methodology quality rating using the controlled trials checklist: **High quality** (++): Majority of criteria met. Little or no risk of bias. Acceptable (+): Most criteria met. Some flaws in the study with an associated risk of bias. Low quality (-): Studies which have poor randomization or treatment allocation concealment with a high risk of bias. Unacceptable (0): Reject.

**Further Risk of Bias conducted using RoB 2 methodology as detailed in Figure 4 of the manuscript. Numbers in () refer to the reference in the primary manuscript.

RCT, randomized controlled trial; TBI, traumatic brain injury

Supplemental Table 8. Evidence Profile for the Management of TBI Patients guided by Viscoelastic Hemostatic Assays

Author(s): JWC, LJK Question: VHA compared to CCT in TBI Setting: Hospital Bibliography:

Baksaas-Aasen K, Gall LS, Stensballe J, Juffermans NP, Curry N, Maegele M, Brooks A, Rourke C, Gillespie S, Murphy J, Maroni R, Vulli amy P, Henriksen HH, Pedersen KH, Kolstadbraaten KM, Wirtz MR, Kleinveld DJB, Schäfer N, Chinna S, Davenport RA, Naess PA, Goslings JC, Eaglestone S, Stanworth S, Johansson PI, Gaarder C, Brohi K. Viscoelastic haemostatic assay augmented protocols for major trauma haemorrhage (ITACTIC): a randomized, controlled trial. Intensive Care Med. 2021 Jan;47(1):49-59. doi: 10.1007/s00134-020-06266-1. Epub 2020 Oct 13. PMID: 33048195; PMCID: PMC7550843

Gonzalez E, Moore EE, Moore HB, Chapman MP, Chin TL, Ghasabyan A, Wohlauer MV, Barnett CC, Bensard DD, Biffl WL, Burlew CC, Johnson JL, Pieracci FM, Jurkovich GJ, Banerjee A, Silliman CC, Sauaia A. Goal-directed Hemostatic Resuscitation of Trauma-induced Coagulopathy: A Pragmatic Randomized Clinical Trial Comparing a Viscoelastic Assay to Conventional Coagulation Assays. Ann Surg. 2016 Jun;263(6):1051-9. doi: 10.1097/SLA.00000000001608. PMID: 26720428; PMCID: PMC5432433.

			Certainty a	ssessment			№ of p	atients	Effec	t		
Nº of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	VHA	сст	Relative (95% Cl)	Absolute (95% CI)	Certainty	Importance
Mortality												
2	randomized trials	serious ^a	serious ^b	serious °	serious ^d	none	21/48 (43.8%)	30/46 (65.2%)	OR 0.39 (0.17 to 0.91)	230 fewer per 1,000 (from 410 fewer to 22 fewer)		CRITICAL

CI: Confidence interval; OR: Odds ratio

Explanations

a. Downgraded for risk of bias in several domains.

b. I^2 46% indicating moderate heterogeneity.

c. Subgroup analysis in both studies.

d. Does not meet optimal information size (OIS), estimated to be 97 per group.